ATAGI issues advice on sedation for COVID-19 vaccination The advice, which is intended to be ‘general in nature’, was discussed at the advisory group’s most recent meeting.
TGA releases vaccine-related myocarditis severity details Fewer than 1% of all likely myocarditis or pericarditis cases linked to mRNA vaccines in Australia have been treated in intensive care.
What impact are boosters having on illness and death in Australia? The distinct patterns of vaccination and infection across different states could already be giving a clear clue on booster efficacy.
Influenza ‘resurgence’ expected in coming months Open borders and low immunity levels has added additional importance to year’s flu vaccine rollout, the Federal Health Secretary has written.
Extra booster dose recommended by ATAGI The rollout of additional COVID-19 vaccine doses for those ‘at greatest risk of severe illness’ will commence ahead of winter to tie in with flu vaccination.
How do we raise child COVID-19 vaccination rates? With the dial barely moving on the proportion of younger children taking vaccines, experts are looking at what else can be done.
T cells provide long-lasting immunity against COVID: Study According to new Australian research, the T cell response to COVID-19 lasts for at least 15 months.
Booster take-up disparities widen Striking contrasts in booster coverage are emerging in different local government areas. What can be done to address the inequities?
‘Surprising’ low antibody response in children with mild COVID The research was conducted on adults and children with similar viral loads following infection with the Wuhan strain.
First safety data on Novavax released Early information on the administration of the Novavax vaccine in Australia is in line with clinical trials data, the TGA has reported.